Gleevec
E584150
orphan drug
protein kinase inhibitor
small molecule drug
targeted cancer therapy
tyrosine kinase inhibitor
Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Gleevec canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6311253 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Gleevec Context triple: [Novartis, notableDrug, Gleevec]
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Gleevec Target entity description: Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
-
A.
Brilinta
Brilinta is a prescription antiplatelet medication (ticagrelor) used to reduce the risk of heart attack, stroke, and cardiovascular death in patients with acute coronary syndrome or a history of myocardial infarction.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
Statements (60)
| Predicate | Object |
|---|---|
| instanceOf |
orphan drug
ⓘ
protein kinase inhibitor ⓘ small molecule drug ⓘ targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedForIndication |
KIT-positive gastrointestinal stromal tumor
ⓘ
Philadelphia chromosome–positive acute lymphoblastic leukemia ⓘ Philadelphia chromosome–positive chronic myeloid leukemia ⓘ aggressive systemic mastocytosis with KIT mutation ⓘ chronic eosinophilic leukemia ⓘ chronic myeloid leukemia ⓘ dermatofibrosarcoma protuberans ⓘ gastrointestinal stromal tumor ⓘ hypereosinophilic syndrome ⓘ metastatic dermatofibrosarcoma protuberans ⓘ myelodysplastic/myeloproliferative diseases associated with PDGFR gene rearrangements ⓘ unresectable dermatofibrosarcoma protuberans ⓘ |
| considered | first successful targeted cancer therapy ⓘ |
| developedBy | Novartis NERFINISHED ⓘ |
| discoveredIn | 1990s ⓘ |
| firstApprovedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| firstApprovedYear | 2001 ⓘ |
| hasAdministrationFrequency | once daily ⓘ |
| hasATCCode | L01EA01 ⓘ |
| hasBrandName | Glivec NERFINISHED ⓘ |
| hasChemicalClass | phenylaminopyrimidine derivative ⓘ |
| hasCommonSideEffect |
diarrhea
ⓘ
edema ⓘ fatigue ⓘ fluid retention ⓘ muscle cramps ⓘ nausea ⓘ rash ⓘ vomiting ⓘ |
| hasDosageForm | tablet ⓘ |
| hasGenericName | imatinib mesylate ⓘ |
| hasInternationalNonproprietaryName | imatinib ⓘ |
| hasLegalStatusInEU | prescription only ⓘ |
| hasLegalStatusInUS | prescription only ⓘ |
| hasMechanismOfAction |
BCR-ABL tyrosine kinase inhibition
ⓘ
KIT (CD117) tyrosine kinase inhibition ⓘ PDGFR tyrosine kinase inhibition ⓘ |
| hasMolecularTargetType | oncogenic fusion protein ⓘ |
| hasPregnancyCategoryUS | D ⓘ |
| hasPrimaryMolecularTarget | BCR-ABL1 fusion protein NERFINISHED ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| isInhibitorOf |
CYP2C9
ⓘ
CYP2D6 NERFINISHED ⓘ CYP3A4 NERFINISHED ⓘ |
| isSubstrateOf | CYP3A4 NERFINISHED ⓘ |
| metabolizedBy |
CYP2C9
NERFINISHED
ⓘ
CYP2D6 NERFINISHED ⓘ CYP3A4 NERFINISHED ⓘ |
| targetsProtein |
ABL1
NERFINISHED
ⓘ
BCR-ABL NERFINISHED ⓘ KIT NERFINISHED ⓘ PDGFRα ⓘ PDGFRβ NERFINISHED ⓘ |
| usedAs |
first-line therapy for chronic-phase CML
ⓘ
second-line therapy for interferon-resistant CML ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Gleevec Description of subject: Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.